Acumen Pharmaceuticals, Inc. (ABOS)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Acumen advances drug ACU193 to Phase 3 with Eisai partnership after Phase 2 success
# 🧾 What This Document Is This is an **Annual Report to Security Holders (ARS)** from Acumen Pharmaceuticals. Think of it as the company's "year-in-review" magazine sent to its shareholders. It's not the official, super-detailed 10-K filed with the SEC, but a more digestible summary that usually g
ABOS shareholders vote on adding 10 million shares to equity plan
# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Acumen Pharmaceuticals. Think of it as an invitation and a voter's guide for the company's **2026 Annual Meeting of Stockholders**. It explains what will be voted on, provides background on the company's leaders and pa
SEC filings
All filings →Insider trades
All insider trades →Acumen Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.